logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12544365 B1

PDFFull Text
Date of Patent:
Feb. 10, 2026

Filed:

Oct. 26, 2022

Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours

Applicant:

Rottapharm Biotech S.r.l., Monza, IT;

Inventors:

Lucio Claudio Rovati, Monza, IT;

Antonio Giordani, Pavia, IT;

Filippo Magaraci, Monza, IT;

Gianfranco Caselli, Milan, IT;

Tiziana Piepoli, Milan, IT;

Daniele Maggioni, Barzio, IT;

Albino Bonazzi, Milan, IT;

Assignee:

Rottapharm Biotech S.R.L., Monza, IT;

Attorneys:

Elmore Patent Law Group, P.C.

Joseph C. Zucchero

Carolyn S. Elmore

Primary Examiner:

Kamal A Saeed

Assistant Examiner:

Sagar undefined Patel

Int. Cl.
CPC ...
A61K 31/438 (2006.01); A61K 31/4353 (2006.01); A61K 31/4458 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 211/60 (2006.01); C07D 221/20 (2006.01);
U.S. Cl.
CPC ...
A61K 31/438 (2013.01); A61K 31/4458 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 211/60 (2013.01); C07D 221/20 (2013.01);
Abstract

The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro [2.5]octane-5-carboxamido)cyclopropyl)benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro [2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.

Find Patent Forward Citations

Rovati, Lucio. (2026). Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours (U.S. Patent No. 12544365). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12544365

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…